#China #Beijing #Lupin Limited #Yabao Pharmaceuticals #Oseltamivir Phosphate

Lupin Limited Launches Oseltamivir Phosphate Oral Suspension in China

Lupin Limited, a leading global pharmaceutical company known for its commitment to affordable healthcare, has achieved a significant milestone with its recent approval for the oseltamivir phosphate oral suspension in China. This important announcement marks the debut of the company’s product in one of the world’s largest pharmaceutical markets, in collaboration with Yabao Pharmaceuticals, a major player in the pediatric medicine sector in China.

On May 22, 2026, the National Medical Products Administration (NMPA) of China granted marketing authorization for the abbreviated new drug application for the oral suspension of oseltamivir phosphate at a concentration of 6 mg/ml. The product is designed to provide effective treatment for influenza A and B, aimed especially at pediatric patients aged two weeks and older. Furthermore, it serves as a preventive measure for individuals aged one year and older, further expanding access to necessary antiviral medications in a country with a vast population.

“This approval signifies an important strategic step into the Chinese market,” stated Fabrice Egros, President of Corporate Development at Lupin. He elaborated on the company's ongoing mission to enhance global healthcare by delivering high-quality, affordable medicines, particularly for children who are often at higher risk during influenza seasons.

The partnership with Yabao Pharmaceuticals not only underscores Lupin’s commitment to pediatric healthcare but also highlights a collaborative effort to leverage each company's strengths in research and development (R&D). Wei Ren, President of Yabao, expressed enthusiasm for this collaboration, stating, “This approval marks a key milestone in our partnership with Lupin and reinforces our commitment to delivering quality pediatric medications. We are eager to expand our R&D portfolio, focusing not only on pediatric therapies but also on chronic diseases affecting adults.”

This launch reflects Lupin’s strategy to broaden its product offerings and enhance its market presence in China. With over 100 markets served globally, Lupin is already recognized for its strong pharmaceutical capabilities, which incorporate both brand and generic products, complex generics, biotechnological products, and active pharmaceutical ingredients (APIs). The company’s comprehensive expertise allows it to meet diverse therapeutic needs, including areas such as respiratory health, cardiovascular care, diabetes management, infectious diseases, gastrointestinal therapies, central nervous system conditions, and women's health.

Lupin boasts a robust manufacturing footprint, with 15 state-of-the-art plants and 7 global R&D centers, supported by a dedicated workforce of over 24,000 professionals. The company remains steadfast in its commitment to improving health outcomes for patients worldwide through innovations in pharmaceuticals, diagnostics, and digital health.

In light of this expansion into China, there are ambitions for further collaboration and partnership opportunities that will enhance Lupin's growth and innovation in the pharmaceutical sector. Both Lupin and Yabao are poised to contribute to the advancement of healthcare solutions that address the unique challenges presented by a vast and diverse patient population.

For more information about Lupin and its product offerings, please visit www.lupin.com, and to learn about Yabao Pharmaceuticals, visit www.yabao.com.cn. This development stands as a testament to the importance of international collaboration in healthcare, aiming to make significant strides in improving patient access to essential medications across the globe.